. P7	3). 1449 REPRODUCED	ATTORNEY DOCKET NO. 2478.1002-016	1	PLICATION NO. 7797,244	
Į	SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 2, 2004 DEC 0 8 2004 Cyluse several sheets if necessary)	FIRST NAMED INVENTOR Scott F. Sneddon	FILING DATE March 10, 2004		
DE		EXAMINER Balasubramanian, V.	CONF 2987	RMATION NO.	GROUP 1624

<u> </u>		<u> </u>		
Com.	DEMAR	U.S	E. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
W	AG	4,944,796	07/31/1990	Wee
	AH			
	AI			
	AJ			
	AK			
	AA2			·
	AB2			
	AC2			
	AD2			·
	AE2			
	AF2			
	AG2			
	AH2			
	Al2			
	AJ2			
	AK2			·
	AA3			
	AB3	-		
	AC3	73 % - 2 m		

V. Balevsubsmann	DATE CONSIDERED 2///05

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2478.1002-016 DIVISIONAL OF APPLICAT 09/852,965 FIRST NAMED INVENTOR Scott F. Sneddon, et al. DIVISIONAL OF APPLICAT 09/852,965 FILING DATE 3/10/04		LICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				
March 2, 2004 (Use several sheets if necessary)	EXAMINER	CONF	TRMATION NO.	GROUP

ļ	U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT				
3	AA	4,997,950	03-05-1991	Murphy et al.				
05	AB	5,932,737	08-03-1999	Itoh et al.				
M	AC	6,048,841	04-11-2000	Baxter et al.				
M	AD	6,306,840 B1	10-23-2001	Adams et al.				
W	AE	6,359,061	03-19-2002	Swayze et al.				
M	AF	6,376,538	04-23-2002	Adams et al.				
,	AG							
	AH							
	Al		•	·				
	AJ							
	AK							
	AA2							
	AB2			·				
	AC2							
	AD2		•					
	AE2							
	AF2							
	AG2							
	AH2							
	Al2	•						
	AJ2							
	AK2							
	AA3							
	AB3			·				
L	AC3							

EXAMINER _	DATE CONSIDERED
V. Belsuramon	B I I De
Vijewwwwamsw	\(\lambda(1703)
2000	

PTD-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

March 2, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2478.1002-016

EXAMINER

DIVISIONAL OF APPLICATION NO. 09/852,965

FIRST NAMED INVENTOR Scott F. Sneddon, et al.

FILING DATE 3/10/04

CONFIRMATION NO.

GROUP

VB 212310b

		I	OREIGN PATENT D	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS	LATION NO
M	AL	0 246 749 A2	. 04-21-1987	Schering Agrochemicals Limited	х	
W	AM	0 330 959 A2	02-20-1989	Bayer AG		х
M	AN	DE 3813986	11-02-1989	Schering AG		х
M	AO	0 372 326 A2	11-24-1989	Bayer AG	х	
M	AP	DE 3928605 A1	03-07-1991	Bayer AG		х
M	AQ	WO 93/17009	09-02-1993	Zenyaku Kogyo Kabushiki Kaisha	х	
m	AL2	WO 99/28301	06-10-1999	E.I. Du Pont De Nemours and Company		
W	AM2	WO 95/12610	05-1999	Institut für Diagnostikforschung GmbH an der Freien Universität Berlin		
M	AN2	DE 2937698 A1	04-02-1981	A. Nattermann & Cie GmbH		х
M	A02	WO 00/26209	05-11-2000	Novartis AG and Novartis- Erfindungen Verwaltungsgesellschaft M.B.H.		
W	AP2	WO 99/00363	01-07-1999	Pharmacia & Upjohn S.P.A.	_	
M	AQ2	WO 01/00576 A1	01-04-2001	Eli Lilly and Company		
W	AL3	WO 01/42192 A2	06-14-2001	Novartis AG		
M	AM3	WO 01/81298 A2	11-01-2001	Bayer Aktiengessellschaft		
	AN3				- · ·	
	AO3					
	AP3					
	AQ3					
	AL4					
,	AM4					
	AN4					

EXAMINER V. Baleronnamen	DATE CONSIDERED	21/105	
@PFDesktop\:ODMA/MHODMA/HBSR05;iManage;457519;1			=

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2478.1002-016	DIVISIONAL OF APPLICATION NO. 09/852,965		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Scott F. Sneddon, et al. FILING DATE 3/10/04			*
March 2, 2004 (Use several sheets if necessary)	EXAMINER	CONFI	RMATION NO.	GROUP

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
M	AR	Waki, et al. "Peptide Synthesis Using the Four-Component Condensation (Ugi Reaction)," J Am Chem Soc., 99(18)6075-6082 (1977).				
M	AS	Tanaka, et al. "Analytical Studies on Mepirizole and its Metabolites. II. Identification of the Human Urinary Metabolites or Mepirizole with Stable Isotope Labeling," Chem and Pharm Bul., 24(4) 804-807 (1976).				
8	AT	Milata, et al. "2,4,6-Tris(Azol-1-YL)-1,3,5-Triazines: A New Class of Multidentate Ligands," Heterocycles, 55(5) 905-924 (2001).				
W	ΑU	Tanaka, et al. "Analytical Studies on Mepirizole and Its Metabolites. III. Gas Chromatographic Determination of Mepirizole and Its Metabolites in Biological Fluids," Chem and Pharm Bul., 24(4) 808-812 (1976).				
8	AV	Bayer, et al., "Preparation and Properties of Mesoionic Oxazolones," Chem. Ber., 103(8):2581-2597 (1970). CA 73:77105, 1970. Article and Abstract				
M	AW	Hazebroucq, G., "2, 3, 4, 5 - Tetrahydro-1H-3-benzazepin-1-ones and hexahydroimidazoisoquinolines," Ann. Chim (Paris) 1(5/6):221-254 (1966) CA 66:2461, 1966. Article and Abstract				
\mathcal{M}	AX	Graninger, et al., "One-year inhibition of tumor necrosis factor-α: a major success or a larger puzzle?," Curr. Opin. Rhematol. 13(3):209-213 (2001).				
W	AY	Shaw, et al., "Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis," Expert Opin. Investig. Drugs 9(7):1469-1478 (2000).				
M	AZ	Wrobel, Jay et al., "Syntheses of Tolrestat Analogues containing Additional Substituents in the Ring and Their Evaluation as Aldose Reductase Inhibitors. Identification of Potent, Orally Active 2-Fluoro Derivatives," J. Med. Chem. 34:2504-2520 (1991).				
M	AR2	Garcia, Jordi et al., "NEW SYNTHETIC "TRICKS". TRIPHENYLPHOSPHINE-MEDIATED AMIDE FORMATION FROM CARBOXYLIC ACIDS AND AZIDES," Tetrahedron Letters, 25(4):4841-4844 (1984).				
m	AS2	Coutts, R.T. et al., "Acetylation and pentafluorobenzoylation of lidocaine metabolites in aqueous solution and identification of derivatives by combined gas chromatography/mass spectrometry," Biomed. Environ. Mss Specrom. 14(4):173-82 (1987). (From Chem. Abstracts, (1987) 107(5), Abstract No. 32462W).				

EXAMINER	V. Balasuranun	DATE CONSIDERED	2/1/05	
@PEDestront-OD	MAA/MODMA AIRCRASSASSASSASSASSASSASSASSASSASSASSASSASS			

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2478.1002-016		isional of app /852,965	LICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 2, 2004	FIRST NAMED INVENTOR Scott F. Sneddon, et al. FILING DATE 3/10/04			
March 2, 2004 (Use several shoets if necessary)	EXAMINER	CONFIRMATION NO. GROU		GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Un	AT2	Kondo, Kazumi et al., "Preparation of amides as vasopressin antagonists, oxytocin antagonists, and vasopressin agonists," Ohtsuka Pharmaceutical Co., Ltd.) 19 April 1989. (From Chem. Abstracts, (1999) 130(11), Abstract No. 139333g).	
9	AUZ '	Davis, Peter W. et al., "Automated Solid-Phase Synthesis of Linear Nitrogen-Linked Compounds," Biotechnology and Bioengineering (Combinatorial Chemistry), 19-28, Winter 2000.	
	AV2		
	AW2		

V. Balasubawan	DATE CONSIDERED & (//os
PFDestron ODM A AMODMA AURS PASSAGE COM	

19;1